UY32367A - Agente preventivo/terapéutico contra el cáncer - Google Patents

Agente preventivo/terapéutico contra el cáncer

Info

Publication number
UY32367A
UY32367A UY0001032367A UY32367A UY32367A UY 32367 A UY32367 A UY 32367A UY 0001032367 A UY0001032367 A UY 0001032367A UY 32367 A UY32367 A UY 32367A UY 32367 A UY32367 A UY 32367A
Authority
UY
Uruguay
Prior art keywords
preventive agent
against cancer
androgen
therapeutic against
preventive
Prior art date
Application number
UY0001032367A
Other languages
English (en)
Inventor
Matsui Hisanori
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42025816&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32367(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY32367A publication Critical patent/UY32367A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se provee un agente preventivo/terapéutico para cáncer independiente de andrógenos, Un agente preventivo/terapéutico para cáncer independiente de andrógenos incluye un derivado de metastina y es particularmente útil como un agente preventivo/terapéutico para cáncer independiente de andrógenos, en particular, cáncer de próstata independiente de andrógenos
UY0001032367A 2008-12-29 2009-12-28 Agente preventivo/terapéutico contra el cáncer UY32367A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20388708P 2008-12-29 2008-12-29

Publications (1)

Publication Number Publication Date
UY32367A true UY32367A (es) 2010-07-30

Family

ID=42025816

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032367A UY32367A (es) 2008-12-29 2009-12-28 Agente preventivo/terapéutico contra el cáncer

Country Status (26)

Country Link
US (1) US20110312898A1 (es)
EP (1) EP2379053A1 (es)
JP (1) JP2012513982A (es)
KR (1) KR20110111420A (es)
CN (1) CN102333520B (es)
AR (1) AR074918A1 (es)
AU (1) AU2009334235A1 (es)
BR (1) BRPI0923663A2 (es)
CA (1) CA2748517A1 (es)
CL (1) CL2011001519A1 (es)
CO (1) CO6382105A2 (es)
CR (1) CR20110374A (es)
DO (1) DOP2011000163A (es)
EA (1) EA019738B1 (es)
EC (1) ECSP11011166A (es)
GE (1) GEP20146001B (es)
IL (1) IL212913A0 (es)
MA (1) MA32935B1 (es)
MX (1) MX2011006170A (es)
NZ (1) NZ593381A (es)
PE (1) PE20110939A1 (es)
TN (1) TN2011000250A1 (es)
TW (1) TW201029660A (es)
UY (1) UY32367A (es)
WO (1) WO2010076896A1 (es)
ZA (1) ZA201103627B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009139298A1 (ja) * 2008-04-30 2009-11-19 国立大学法人京都大学 メタスチン誘導体およびその用途
CA2785021C (en) * 2009-12-22 2019-03-05 Takeda Pharmaceutical Company Limited Sustained-release formulation
MA34321B1 (fr) * 2010-06-25 2013-06-01 Takeda Pharmaceutical Formulation à libération prolongée
JP6253146B2 (ja) * 2014-02-04 2017-12-27 国立大学法人山口大学 新規なペプチド誘導体及びこれを含有する医薬
EA201700154A1 (ru) * 2014-10-20 2017-08-31 Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" Фармацевтический состав лечебно-профилактического действия и способ его приготовления
WO2018060438A1 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating female infertility

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003292696A1 (en) 2002-12-26 2004-08-10 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
US6800611B2 (en) * 2003-01-06 2004-10-05 Takeda Chemical Industries, Ltd. Metastin derivatives and their use
ZA200610820B (en) * 2004-06-25 2008-08-27 Takeda Pharmaceutical Metastin derivatives and use thereof
EP2113513B1 (en) * 2004-06-25 2016-05-18 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (zh) * 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途

Also Published As

Publication number Publication date
NZ593381A (en) 2013-01-25
CO6382105A2 (es) 2012-02-15
US20110312898A1 (en) 2011-12-22
KR20110111420A (ko) 2011-10-11
CN102333520A (zh) 2012-01-25
TN2011000250A1 (en) 2012-12-17
EA019738B1 (ru) 2014-05-30
DOP2011000163A (es) 2011-07-31
MX2011006170A (es) 2011-06-27
MA32935B1 (fr) 2012-01-02
BRPI0923663A2 (pt) 2016-01-19
ZA201103627B (en) 2012-09-26
CA2748517A1 (en) 2010-07-08
WO2010076896A1 (en) 2010-07-08
EP2379053A1 (en) 2011-10-26
AR074918A1 (es) 2011-02-23
JP2012513982A (ja) 2012-06-21
CL2011001519A1 (es) 2012-03-16
GEP20146001B (en) 2014-01-10
PE20110939A1 (es) 2012-01-19
ECSP11011166A (es) 2011-07-29
AU2009334235A1 (en) 2010-07-08
CR20110374A (es) 2011-09-19
TW201029660A (en) 2010-08-16
CN102333520B (zh) 2013-11-06
IL212913A0 (en) 2011-07-31
EA201100882A1 (ru) 2011-12-30

Similar Documents

Publication Publication Date Title
UY31432A1 (es) Compuestos de diarilhidantoina
UY32367A (es) Agente preventivo/terapéutico contra el cáncer
BRPI0924549A2 (pt) nano fotomedicamentos como alvo para terapia fotodinâmica do câncer
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
NI201500088A (es) Inhibidores de histona desmetilasa
GT200900124A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
MX2011011431A (es) Composicion para el tratamiento de cancer de prostata.
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
CR20110560A (es) Métodos de tratamiento para tumores sólidos
CL2011002595A1 (es) Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
CR20120413A (es) Derivados de fumarato de ácido graso y sus usos
EA201290838A1 (ru) Конъюгаты пирролбензодиазепина направленного действия
EP2517022A4 (en) METABOLOMIC PROFILING OF PROSTATE CANCER
BRPI0908127A2 (pt) Método para o tratamento do câncer da próstata com degarelix antagonista do gnrh
SV2010003593A (es) Nuevos herbicidas
PH12014501639A1 (en) Pharmaceutical compositions and methods
BR112012002797A2 (pt) tratamento de câncer de próstata
BR112013015889A2 (pt) unidade de raio-x móvel, métodos para fabricar uma unidade de raio-x móvel e para suprir um feixe de raio-x para irradiar uma lesão superficial, e, tampa de aplicador para uma unidade de raio-x.
CL2015000715A1 (es) Anti-androgenos para el tratamiento de cáncer prostatico no metastasico y resistente de castracion
AR076849A1 (es) Composicion de tratamiento para el cabello.
BRPI1011912A2 (pt) l-serina para uso como medicamento para prevenir e/ou tratar uma reação inflamatória da pele.
BR112012000185A2 (pt) composição para o tratamento de hiperplasia benigna da próstata
ECSP11011550A (es) Procedimientos de uso del factor liberador de corticotropina para eltratamiento de cáncer
AR080607A1 (es) Composiciones de acabado del cuero que comprenden derivados de dioxolano

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190129